Hospital
Dignity Health
Dignity Health was paid $45.14M by Medicaid between Jan 2018 and Dec 2024, across 162 billing codes. Its largest line is 0450, Emergency room services — 22% of everything it billed.
33Billing provider infoDIGNITY HEALTH
FOLSOM, CA 95630
FOLSOM, CA 95630
33aNPI1356389878assigned 06/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$45.14M
24GClaims539,945
24DCodes billed162
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#68 of 410
Median peer was paid$6.90M
This provider vs. median6.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MORISSETTE, DANIEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 96,471 | $6.65M | |
| 2019 | 93,581 | $7.09M | |
| 2020 | 61,654 | $5.04M | |
| 2021 | 72,497 | $6.09M | |
| 2022 | 74,269 | $6.76M | |
| 2023 | 79,397 | $7.33M | |
| 2024incomplete | 62,076 | $6.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 22% | 29,104 | 26,587 | $9.78M |
| A9150 | Non-prescription drugs | 14% | 22,867 | 11,735 | $6.52M |
| 36415 | Collection of venous blood by venipuncture | 13% | 29,076 | 25,763 | $6.05M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.5% | 19,049 | 17,976 | $3.39M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.4% | 20,853 | 19,731 | $2.91M |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 5.9% | 7,723 | 5,449 | $2.64M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.7% | 7,505 | 7,063 | $2.11M |
| 80053 | Comprehensive metabolic panel | 2.8% | 43,078 | 40,346 | $1.27M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 4,709 | 4,486 | $937K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 4,184 | 4,073 | $912K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 5,235 | 5,080 | $909K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,374 | 7,182 | $450K |
150 more codes
| 71045 | Radiologic examination, chest; single view | <1% | 10,464 | $432K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,437 | $370K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,323 | $319K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 5,419 | $316K |
| 0250 | <1% | 6,660 | $296K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,656 | $295K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,507 | $295K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,844 | $278K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 41,452 | $268K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,620 | $251K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,332 | $233K |
| Z7502 | <1% | 4,766 | $179K | |
| 84484 | <1% | 9,448 | $168K | |
| 0360 | <1% | 272 | $149K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 795 | $146K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,001 | $141K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,080 | $125K |
| J3490 | Unclassified drugs | <1% | 19,319 | $118K |
| 0270 | <1% | 14,692 | $114K | |
| 81001 | <1% | 12,457 | $107K | |
| 0762 | <1% | 30 | $99K | |
| 81003 | <1% | 6,218 | $93K | |
| 84703 | <1% | 9,127 | $88K | |
| 73630 | <1% | 1,374 | $88K | |
| 87040 | <1% | 5,146 | $84K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 577 | $80K |
| 73610 | <1% | 1,007 | $79K | |
| 87081 | <1% | 1,733 | $79K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,416 | $78K |
| 83690 | <1% | 9,244 | $75K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,437 | $65K |
| 73564 | <1% | 984 | $64K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,721 | $61K |
| 93971 | <1% | 1,022 | $61K | |
| 82962 | <1% | 2,884 | $60K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,816 | $59K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,039 | $59K |
| 73030 | <1% | 743 | $57K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,538 | $55K |
| 73130 | <1% | 746 | $55K | |
| 83880 | <1% | 2,799 | $54K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,437 | $54K |
| 83605 | <1% | 4,913 | $49K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 364 | $47K |
| 73110 | <1% | 538 | $43K | |
| 96376 | <1% | 1,217 | $40K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,261 | $39K |
| 87077 | <1% | 1,682 | $33K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,926 | $33K |
| 99199 | Unlisted special service, procedure or report | <1% | 81 | $33K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 852 | $32K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 906 | $32K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,193 | $30K |
| 76830 | Ultrasound, transvaginal | <1% | 803 | $30K |
| 0710 | <1% | 403 | $28K | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | <1% | 27 | $26K |
| C1781 | Mesh (implantable) | <1% | 28 | $25K |
| 74018 | <1% | 515 | $24K | |
| A9270 | Non-covered item or service | <1% | 2,673 | $24K |
| 87631 | <1% | 421 | $23K | |
| Z7610 | <1% | 2,257 | $23K | |
| 85379 | <1% | 2,287 | $22K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,938 | $21K |
| 83735 | <1% | 2,461 | $21K | |
| 72100 | <1% | 450 | $20K | |
| G0378 | Hospital observation service, per hour | <1% | 31 | $20K |
| 81025 | <1% | 2,224 | $19K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,027 | $19K |
| 85730 | <1% | 3,098 | $19K | |
| 85610 | <1% | 3,790 | $16K | |
| 85027 | <1% | 3,098 | $16K | |
| 84702 | <1% | 1,227 | $16K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 406 | $16K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,806 | $14K |
| 76801 | <1% | 465 | $13K | |
| 88304 | <1% | 46 | $13K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,196 | $13K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,215 | $12K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,321 | $12K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 32 | $12K |
| 72131 | <1% | 44 | $12K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,093 | $10K |
| 0324 | <1% | 48 | $9K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 137 | $8K |
| 82553 | <1% | 684 | $8K | |
| 12001 | <1% | 58 | $8K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,262 | $8K |
| 29125 | <1% | 165 | $7K | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 247 | $6K |
| 82550 | <1% | 842 | $6K | |
| 73080 | <1% | 72 | $6K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 488 | $6K |
| 87186 | <1% | 1,320 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 604 | $5K |
| 72040 | <1% | 53 | $5K | |
| 97139 | <1% | 449 | $5K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 103 | $5K |
| 90715 | <1% | 577 | $4K | |
| 94644 | <1% | 170 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,190 | $4K |
| 85007 | <1% | 1,231 | $4K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 58 | $4K |
| 86141 | <1% | 486 | $4K | |
| 73140 | <1% | 40 | $4K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 42 | $3K |
| 47562 | <1% | 12 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 31 | $3K |
| 97750 | <1% | 104 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,186 | $2K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 181 | $2K |
| 93017 | <1% | 33 | $2K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 885 | $2K |
| 86901 | <1% | 305 | $2K | |
| 80061 | Lipid panel | <1% | 138 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 912 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 151 | $2K |
| 73502 | <1% | 14 | $1K | |
| 85651 | <1% | 205 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 297 | $1K |
| 10060 | <1% | 15 | $1K | |
| 86308 | <1% | 232 | $967.87 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 336 | $862.36 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 383 | $848.85 |
| 96367 | <1% | 31 | $731.03 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 271 | $704.89 |
| 74019 | <1% | 12 | $682.38 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 237 | $672.35 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 41 | $656.53 |
| 87070 | <1% | 13 | $656.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 287 | $612.77 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 22 | $394.58 |
| 0012A | <1% | 16 | $390.36 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 80 | $343.02 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 139 | $252.78 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 18 | $228.94 |
| 86885 | <1% | 28 | $181.51 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 17 | $160.34 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 85 | $144.90 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 60 | $91.76 |
| 86900 | <1% | 28 | $84.62 | |
| 70486 | <1% | 12 | $76.13 | |
| 87147 | <1% | 12 | $73.12 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 13 | $45.57 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 19 | $31.15 |
| 84145 | <1% | 14 | $21.08 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 25 | $0.00 |
| 87205 | 0% | 12 | $0.00 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 12 | $0.00 |
| A4218 | Sterile saline or water, metered dose dispenser, 10 ml | 0% | 27 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORISSETTE, DANIEL (CHIEF FINANCIAL OFFICER)
Parent organizationDIGNITY HEALTH
| Provider | Location | Paid |
|---|---|---|
| Dignity Health | San Bernardino, CA | $133.09M |
| Dignity Health | Phoenix, AZ | $126.19M |
| Dignity Health | Bakersfield, CA | $109.22M |
| Dignity Health | Merced, CA | $106.54M |
| Dignity Health | Carmichael, CA | $97.28M |
| Dignity Health | Oxnard, CA | $96.24M |
| Dignity Health | Redding, CA | $92.21M |
| Dignity Health | Long Beach, CA | $59.98M |
| Dignity Health | Sacramento, CA | $45.52M |
| Dignity Health | Red Bluff, CA | $39.92M |
| Dignity Health | Santa Cruz, CA | $33.59M |
| Dignity Health | Gilbert, AZ | $28.49M |
| Dignity Health | Glendale, AZ | $26.30M |
| Dignity Health | Henderson, NV | $18.73M |
| Dignity Health | Mount Shasta, CA | $15.62M |
| Dignity Health | Henderson, NV | $8.52M |
| Dignity Health | Las Vegas, NV | $7.93M |
| Dignity Health | Camarillo, CA | $6.31M |
| Dignity Health | Santa Maria, CA | $5.79M |
| Dignity Health | Corning, CA | $3.24M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.